Odds ratios (ORs) and hazard ratios (HRs) for quantitative variables are presented in Table 1. The HRD score is a sum of three previously described metrics: LOH, loss of heterozygosity [1]; TAI, telomeric allelic imbalance [2]; and LST, large-scale state transitions [3]. Previous studies have shown that the HRD score is significantly associated with response to DNA-damaging agents [4,5]. This study examined whether an HRD test was predictive of response or overall survival (OS) in a HGSOC cohort treated with platinum monotherapy from the SCOTROC-4 phase 3 trial [6].

RESULTS

The HRD score

Table 1. Patient and Tumor Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Non-Deficient</th>
<th>Deficient</th>
<th>OR (95% CI)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA125 response</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>3.55 (1.63, 7.74)</td>
<td>4.73 (1.87, 11.95)</td>
<td>0.00054</td>
<td></td>
</tr>
<tr>
<td>Partial</td>
<td>2.07 (1.18, 3.63)</td>
<td>2.51 (1.29, 4.88)</td>
<td>0.023</td>
<td></td>
</tr>
<tr>
<td>Univariate</td>
<td>3.69 (1.49, 9.15)</td>
<td>4.46 (1.10, 18.10)</td>
<td>0.013</td>
<td></td>
</tr>
<tr>
<td>Multivariate</td>
<td>4.03 (2.19, 7.43)</td>
<td>7.07 (2.89, 17.78)</td>
<td>0.00058</td>
<td></td>
</tr>
</tbody>
</table>

CONCLUSIONS

• HR deficiency and BRCA1/2 mutation status were associated with improved PFS (p=0.0058, 0.023 respectively) and OS (p=0.0045, 0.028 respectively) in an independent manner from known prognostic clinical factors (Table 3).

REFERENCES


ACKNOWLEDGMENTS

HPO testing was performed by Myriad Genetics, Inc.

Support was provided by: